Randomized controlled trial· 2024
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, Steen O, Lucas KJ, et al.
The Lancet Diabetes & Endocrinology
- PubMed
- 38330987
- Evidence level
- moderate
- Verification
- verified
Summary
Randomized phase 2 dose-finding trial of once-weekly survodutide or placebo in adults with overweight or obesity without diabetes.
Limitations
The study was phase 2 and not powered for long-term clinical outcomes or rare safety events. Treatment discontinuation and gastrointestinal tolerability affect interpretation.